A double‐blind, placebo‐controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome - Concepedia

Concepedia

Publication | Closed Access

A double‐blind, placebo‐controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

107

Citations

9

References

2004

Year

Henry Nyhlin, Christen J. Bang, L Elsborg, J Silvennoinen, Ingar Holme, P. Rüegg, John J. Jones, Amy W. Wagner

Scandinavian Journal of Gastroenterology

Abstract

Tegaserod 6 mg b.i.d. is an effective, safe and well-tolerated treatment in patients suffering from IBS without diarrhoea as primary bowel symptom.

References

	Year	Citations

Page 1